Clinical trial NCT02472171: Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans
Official title: Suppression of Postprandial Monocyte Activation by Fruit Rich in Anti-inflammatory Polyphenols or Docosahexaenoic Acid in Humans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inflammation
Keywords: n-3 polyunsaturated fatty acids
blueberries
Lead sponsor: USDA, Western Human Nutrition Research Center
Sponsor class: FED
Collaborators: name: University of California, Davis
First posted: 2015-06-15
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The overall goal of the research study is to determine whether a high-fat meal causes postprandial (after meal) inflammation, and whether eating n-3 polyunsaturated fatty acids (PUFAs) or blueberries that are rich in anti-inflammatory polyphenols suppress the inflammation in healthy people.

Detailed description: Chronic inflammation is one of the key etiological conditions associated with the development and progression of chronic diseases including Alzheimer's disease, atherosclerotic cardiovascular disease, insulin resistance, obesity and cancer. The causes of chronic inflammation and the role of diet in suppressing inflammation are challenging research questions. Pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), nucleotide-binding oligomerization domain proteins (NODs), and the inflammasome expressed in innate immune cells can be activated by a variety of endogenous molecules derived from tissue injury and diet (in particular saturated fatty acids), eliciting inflammation. Dysregulated induction of PRR-mediated inflammation is known to promote the development of chronic diseases. Previous studies showed that saturated fatty acids can activate toll-like receptor 4 (TLR4) and nucleotide-binding oligomerization domain 2 (NOD2) mediated signaling pathways, whereas, docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid, and certain polyphenols (quercetin, luteolin, Epigallocatechin gallate (EGCG), resveratrol) rich in certain fruits and vegetables inhibit TLR4 or NOD2-mediated inflammation. In addition, numerous studies have demonstrated that TLR4 knockout mice were protected from high saturated fat diet-induced inflammation and insulin resistance, suggesting that high fat diet-induced inflammation and insulin resistance are at least partly mediated through the activation of TLR4. Direct evidence of saturated fatty acids derived from a high fat meal activating PRRs in humans has not been demonstrated. Thus, the investigators propose to determine whether saturated fatty acids derived from a high saturated fat meal activate blood monocytes through PRRs and whether dietary DHA and freeze-dried blueberry powder can suppress high saturated fat meal-induced inflammation by inhibiting PRR activation.

The experimental procedures and the study activities will last for approximately 9 weeks. There will be three test days, scheduled 4 weeks apart. On the test days there will be four blood draws (one fasting blood draw and three postprandial blood draws at 1-hour, 3-hour and 6-hour after breakfast, respectively). Three endothelial function measurements (EndoPAT) will be carried out each test day. A pre-test dinner meal will be provided to the subject to eat the night before each test day. Subjects will be asked to follow and record a low antioxidant and polyphenol diet of their own choosing for 3 days prior to each test day. This includes minimizing tea, wine, coffee, chocolate, fruits, vegetables, whole grains, soy, herbs, spices, condiments, and fatty fish. All volunteers will participate in all test days, receiving in randomize cross-over fashion the following treatments:

A. High saturated fat diet, placebo powder, sunflower oil. B. High saturated fat diet, blueberry powder, sunflower oil. C. High saturated fat diet, placebo powder, DHA.

The high saturated fat meal will be identical in all treatments and may contain tortilla, cheddar cheese, beef sausage, scrambled eggs, and a smoothie style drink containing sugar, vanilla extract, oil, whole milk yogurt and the ingredients for masking treatments. The placebo powder may contain Beneprotein® (Nestlé Nutrition), Benefiber® (Novartis), oil, sugar, artificial food-grade blueberry flavor, and artificial food-grade blue and red colors. The blueberry powder (equivalent to four 1/2 cup servings) will be obtained from the U.S. Highbush Blueberry Council (Folsom, CA). The DHA will be obtained from Martek Biosciences. Blueberry or placebo powder and the DHA or sunflower oil will be combined into a blueberry flavored smoothie style drink. Neither the study subjects or the investigators will know which treatment is provided on which test day.

Eligibility criteria: Inclusion Criteria:

* Body Mass Index of 18-25 kg/m2
* Complete Blood Count (CBC) within normal limits
* Blood chemistry panel within normal limits

Exclusion Criteria:

* following a vegetarian diet
* smoke or use tobacco products
* consume more than one alcoholic beverage per day (defined as 1 oz. distilled liquor, 3 oz. wine, or 12 oz. beer)
* taking any cholesterol lowering
* taking blood pressure medication
* taking non-steroidal anti-inflammatory drugs (NSAIDS) more than once a week and for 3 days before each test day
* taking steroids for asthma or other inflammatory states
* taking thyroid-regulating drugs
* taking over-the-counter weight loss products
* allergies or sensitivities to foods or ingredients in the test meals, especially blueberries or DHA
* taking fish or algae oil or other dietary supplements and unwilling to stop the supplements for the duration of the study (multivitamin is OK)
* Women who are pregnant, lactating or planning a pregnancy
* fasting blood cholesterol greater than 240 mg/dL
* fasting blood triglyceride greater than 300mg/dL
* hemoglobin less than 11.5 mg/dL
* blood pressure greater than 140/90 mmHg
* metabolic diseases such as diabetes mellitus, hypothyroidism, kidney disease, liver disease, bleeding disorders, autoimmune diseases, other inflammatory disease, or cancer unless greater than 5 years remission

Primary outcomes:
measure: Change in Monocyte activation in whole blood
timeFrame: Measured at 0, 1, 3, and 6 hours after high fat meal with blueberries, DHA or placebo
Secondary outcomes:
measure: Change in surface markers for monocyte activation
timeFrame: Measured at 0, 1, 3, and 6 hours after high fat meal with blueberries, DHA or placebo
measure: Change in systemic inflammation
timeFrame: Measured at 0, 1, 3, and 6 hours after high fat meal with blueberries, DHA or placebo
measure: Change in systemic inflammation measured indirectly
timeFrame: Measured at 0, 3, and 6 hours after high fat meal with blueberries, DHA or placebo
measure: Change in gene expression profile in whole blood
timeFrame: Measured at 0, 1, 3, and 6 hours after high fat meal with blueberries, DHA or placebo
measure: Change in blood lipids
timeFrame: Measured at 0, 1, 3, and 6 hours after high fat meal with blueberries, DHA or placebo
measure: Change in endothelial function measurements
timeFrame: Measured at 0, 3, and 6 hours after high fat meal with blueberries, DHA or placebo
Other outcomes:
Locations:
city: Davis
country: United States
facility: USDA, ARS, Western Human Nutrition Research Center
state: California
Study officials:
affiliation: USDA, ARS, Western Human Nutrition Research Center
name: Daniel Hwang, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mo Z, Huang S, Burnett DJ, Rutledge JC, Hwang DH. Endotoxin May Not Be the Major Cause of Postprandial Inflammation in Adults Who Consume a Single High-Fat or Moderately High-Fat Meal. J Nutr. 2020 May 1;150(5):1303-1312. doi: 10.1093/jn/nxaa003.